Recent research featured in JCO Precision Oncology reveals that the Prolaris Test by Myriad Genetics effectively forecasts the advantages of hormone therapy for men diagnosed with localized prostate cancer.
In: Plus Company Updates, 2024-05-18
Zeitungsartikel
Zugriff:
Titel: |
Recent research featured in JCO Precision Oncology reveals that the Prolaris Test by Myriad Genetics effectively forecasts the advantages of hormone therapy for men diagnosed with localized prostate cancer.
|
---|---|
Zeitschrift: | Plus Company Updates, 2024-05-18 |
Veröffentlichung: | 2024 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|